Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis reports positive Phase 3 PALLADIUM results in uncontrolled asthma

September 30, 2019
Sales and Marketing

Novartis has announced that its investigational, once-daily, fixed-dose inhaled QMF149 (indacaterol acetate and mometasone furoate) was superior to mometasone furoate …

News
lynparza

AZ and Merck’s ovarian cancer combo improves progression-free survival

September 30, 2019
Sales and Marketing

AstraZeneca and Merck have announced that their combination treatment for newly diagnosed ovarian cancer significantly improved progression free survival. The …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 27, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten

Another week comes to a close, and it’s time to review the biggest stories of the week. Check out the …

News
takeda_deerfield_hq

Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis

September 27, 2019
Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …

News
abbvie_0

AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients

September 27, 2019
Medical Communications, Sales and Marketing AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma

The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the …

News
darzalex-product-shot---100mg-vial-2-hr

FDA approves Genmab’s Darzalex combo in newly diagnosed multiple myeloma

September 27, 2019
Medical Communications, Sales and Marketing FDA, Genmab, darzalex, pharma

Genmab’s CD38 inhibitor Darzalex (daratumumab) has been awarded marketing authorisation from the FDA in combination with bortezomib, thalidomide and dexamethasone …

News
Catapult Stevenage site

Cell and Gene Therapy Catapult doubles capacity at UK site

September 26, 2019
Manufacturing and Production, Medical Communications

The United Kingdom’s Cell and Gene Therapy Catapult (CGT Catapult) has added six additional modules of cleanroom space at its …

News
research

Male infertility linked to prostate cancer risk

September 26, 2019
Research and Development

Research published in the British Medical Journal has found a link that men who have fertility treatment have a higher …

News

Iran reveals plans to domestically produce 135 strategic drugs

September 26, 2019
Manufacturing and Production Iran, pharma, production

Iran has announced plans to promote self-sufficiency within the country with regard to its medicines production, with an aim of …

News
Uk flag

UK announces research plan on evolving global health threats

September 26, 2019
Research and Development

The UK’s Chief Medical Officer, Professor Dame Sally Davies has announced funding for projects to help combat antimicrobial resistance (AMR) …

News

NICE shoots down Novartis’ migraine drug Aimovig outside of Scotland

September 26, 2019
Sales and Marketing Aimovig, NICE, Novartis, UK, migraine, pharma

NICE has announced its decision to reject Novartis’ drug Aimovig (erenumab) for use on the NHS in England and Wales …

News

Springworks’ nirogacestat receives EC orphan status

September 26, 2019
Research and Development

Springworks, a clinical-stage biopharmaceutical company focusing on severe rare disease and cancer has been granted orphan status by the European …

News
610px-jeremy_corbyn_2016_labour_party_conference_10

Corbyn announces plan to ‘put public health before private profit’

September 25, 2019
Research and Development

Jeremy Corbyn has announced a new plan to set up a state-run drugs manufacturer to sell cheap medications to the …

News
takeda_world

Takeda’s investigational therapy shows promise as cytomegalovirus treatment

September 25, 2019
Research and Development, Sales and Marketing Takeda, cytomegalovirus, maribavir, pharma

New Phase 2 data has been released on Takeda’s investigational antiviral therapy TAK-620 (maribavir) in patients with cytomegalovirus (CMV) infection …

News
novartis_side_building

Novartis blames former AveXis execs for Zolgensma data manipulation

September 25, 2019
Research and Development

Novartis has placed blame on former executives Brian and Allan Kaspar for the manipulation of data behind its $2.1 million …

News
opdivo_1_1

EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma

September 25, 2019
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …

News
Ipsen Logo

Ipsen announces positive phase 3 results in limb spastic hemiparesis

September 24, 2019
Manufacturing and Production, Research and Development

Ipsen has announced results from its ENGAGE study for the combination of Dysport (abobotulinumtoxinA) alongside Guided Self-rehabilitation contracts (GSC) which …

News
celltrion1

Celltrion’s subcutaneous infliximab biosimilar secures CHMP recommendation

September 24, 2019
Manufacturing and Production, Sales and Marketing EMA, EU, Europe, biosimilar, celltrion, infliximab, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has given its recommendation to Celltrion’s CT-P13 SC, the subcutaneous …

News
Takeda HQ

Evotec and Takeda enter into multi therapeutic area collaboration

September 24, 2019
Manufacturing and Production, Research and Development

Evotec have announced a strategic, multi-year drug discovery collaboration with Takeda, with both companies aiming to establish at least five …

News

Bayer’s Vitravki becomes first EU-approved tumour-agnostic therapy

September 24, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Cancer, Vitravki, pharma

Bayer has announced that its tyrosine receptor kinase (TRK) inhibitor Vitrakvi (larotrectinib) has scored approval from the European Commission for …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026